Skip to main content
Back
Watch Compare

TScan Therapeutics, Inc.

Data quality: 100%
TCRX
Nasdaq Manufacturing Chemicals
$1.05
▼ $0.01 (-0.94%)
Mkt Cap: 59.46 M
Price
$1.05
Mkt Cap
59.46 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Revenue grew 0.45% annually over 5 years — modest growth
Debt/Equity of 0.23 — conservative balance sheet
Negative free cash flow of -139.73 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 266.20%
Capital intensive — 42.68% of revenue goes to capex

Growth

Revenue Growth (5Y)
0.45%
Below sector avg (1.82%)
Revenue (1Y)266.65%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-80.92%
Below sector avg (-53.41%)
ROIC-42.89%
Net Margin-1256.81%
Op. Margin-1315.38%

Safety

Debt / Equity
0.23
Below sector avg (0.31)
Current Ratio6.44
Interest Coverage-49.05

Valuation

PE (TTM)
-0.46
Above sector avg (-1.48)
P/B Ratio0.41
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -0.5 -1.5
P/B 0.4 1.6
ROE % -80.9 -53.4
Net Margin % -1256.8 -41.5
Rev Growth 5Y % 0.5 1.8
D/E 0.2 0.3

ETFs Holding This Stock

SURI logo SURI Simplify Propel Opportunities ETF
2.38% weight
BRSIX BRSIX
0.15% weight
SHISX SHISX
0.01% weight
SHSCX SHSCX
0.01% weight
SHSAX SHSAX
0.01% weight
GSSC logo GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF
0.00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 266.65% Revenue Growth (3Y) -29.96%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 0.45% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 10.33 M Net Income (TTM) -129.77 M
ROE -80.92% ROA -46.28%
Gross Margin N/A Operating Margin -1315.38%
Net Margin -1256.81% Free Cash Flow (TTM) -139.73 M
ROIC -42.89% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.23 Current Ratio 6.44
Interest Coverage -49.05 Asset Turnover 0.04
Working Capital 158.96 M Tangible Book Value 144.02 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.46 Forward P/E N/A
P/B Ratio 0.41 P/S Ratio 5.76
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -234.98%
Market Cap 59.46 M Enterprise Value -77.63 M
Per Share
EPS (Diluted TTM) -1.00 Revenue / Share 0.18
FCF / Share -2.46 OCF / Share -2.38
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 42.68% FCF Conversion 107.68%
SBC-Adj. FCF -151.95 M Growth Momentum 266.20

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 10.33 M 2.82 M 21.05 M 13.54 M 10.14 M
Net Income -129.77 M -127.50 M -89.22 M -66.22 M -48.63 M
EPS (Diluted) -1.00 -1.14 -1.36 -2.75 —
Gross Profit — — — — —
Operating Income -135.81 M -134.82 M -93.46 M -66.64 M -48.64 M
EBITDA — — — — —
R&D Expenses 114.15 M 107.35 M 88.15 M 59.82 M 44.95 M
SG&A Expenses — — — — —
D&A 2.90 M 4.10 M 5.40 M 5.10 M 3.30 M
Interest Expense 2.77 M 3.65 M 3.76 M 1.18 M —
Income Tax 0.0 — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 228.79 M 371.12 M 272.15 M 199.09 M 188.11 M
Total Liabilities 105.67 M 130.15 M 121.28 M 99.66 M 27.33 M
Shareholders' Equity 123.12 M 240.97 M 150.87 M 99.43 M 160.78 M
Total Debt 32.53 M 32.07 M 30.05 M 29.29 M —
Cash & Equivalents 152.41 M 178.69 M 133.36 M 120.03 M 161.41 M
Current Assets 157.21 M 292.72 M 194.24 M 124.13 M 165.65 M
Current Liabilities 18.70 M 35.96 M 29.82 M 17.31 M 21.34 M